The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.
John P. Neoptolemos
Disclosure not yet available
William Greenhalf
Disclosure not yet available
Trevor F. Cox
Disclosure not yet available
Eithne Costello
Disclosure not yet available
Victoria Shaw
Disclosure not yet available
Juan W. Valle
Disclosure not yet available
Fareeda Y. Coxon
Disclosure not yet available
Jonathan Wadsley
Disclosure not yet available
David Propper
Disclosure not yet available
Paul J. Ross
Disclosure not yet available
Srinivasan Madhusudan
Disclosure not yet available
Tom Roques
Disclosure not yet available
David Cunningham
Disclosure not yet available
Martin McKinlay Eatock
Disclosure not yet available
Tim Iveson
Disclosure not yet available
Kinnari Patel
Disclosure not yet available
Angel Garcia-Alonso
Disclosure not yet available
Gemma Nanson
Disclosure not yet available
Gary Middleton
Disclosure not yet available